Synergistic Rifabutin and Colistin Reduce Emergence of Resistance When Treating Acinetobacter baumannii

Recently, we reported rifabutin hyperactivity against Acinetobacter baumannii. We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic in vitro and in vivo, and low-dose colisti...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Jiaqi, Yan, Jun, Reyna, Zeferino, Slarve, Matt, Lu, Peggy, Spellberg, Brad, Luna, Brian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Susceptibility
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8097462/
https://www.ncbi.nlm.nih.gov/pubmed/33468472
http://dx.doi.org/10.1128/AAC.02204-20
Descripción
Sumario:Recently, we reported rifabutin hyperactivity against Acinetobacter baumannii. We sought to characterize potential interactions between rifabutin and colistin, the last-resort drug for carbapenem-resistant infections. Rifabutin and colistin were synergistic in vitro and in vivo, and low-dose colistin significantly suppressed emergence of resistance to rifabutin. Thus, this combination is a promising therapeutic option for highly resistant A. baumannii infections.

Ejemplares similares